NCT04425902 - Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions

HIV Infections

Interventions

DRUG

GSK3640254 200 mg

GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.

DRUG

Caffeine 200 mg

Caffeine will be available as oral tablets at unit dose strength of 200 mg.

DRUG

Metoprolol 100 mg

Metoprolol will be available as oral tablets at unit dose strength of 100 mg.

DRUG

Montelukast 10 mg

Montelukast will be available as oral tablets at unit dose strength of 10 mg.

DRUG

Flurbiprofen 100 mg

Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.

DRUG

Omeprazole 40 mg

Omeprazole will be available as oral capsules at unit dose strength of 40 mg.

DRUG

Midazolam 5 mg (2.5 mL)

Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).

DRUG

Digoxin 0.25 mg

Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.

DRUG

Pravastatin 40 mg

Pravastatin will be available as oral tablet at unit dose strength of 40 mg.

Trial Locations (1)

GSK Investigational Site, Las Vegas